がん診断市場規模、シェア、動向分析レポート：製品タイプ別、用途別、最終用途別、検査タイプ別、対象範囲別、地域別、セグメント予測、2025年～2030年

がん診断市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界のがん診断市場規模は2030年までに1,550億7,000万米ドルに達すると予測されています。

同市場は2025～2030年にかけてCAGR 6.14％で成長すると予測されています。複数の組織によるがんに関する意識向上プログラムの増加が、世界の診断製品の需要増加の主要要因です。全国子宮頸がん連合、WHO、CDC、米国予防サービス作業部会などが子宮頸がん検診を増やすために行っているパートナーシップや協力関係は、予測期間中の市場成長を押し上げると予想される主要要因の一つです。

そのため、いくつかの国では、早期診断のための検診を増やし、既存の患者を支援するための対策を実施しています。例えば、Ayushman Bharatと首相国家救済基金（Prime Minister's National Relief Fund）は、治療中に援助を必要とする患者のためにインド政府によって開始されました。同様に、インド政府のバイオテクノロジー省はCancer Research UKと契約を結び、診断と治療への安価なアプローチのための調査を行っています。

液体生検ソリューションは、臨床応用が容易であることから、MCED検査として採用されるケースが増えています。近年では、包括的かつ複数のがん診断アプローチで規制当局の承認を得ています。このセグメントにおける画期的な進歩や早期発見のための進行中の研究が市場の成長に寄与しています。さらに、循環腫瘍DNA、細胞外小胞、循環腫瘍細胞などの技術は、より良いがん治療への道を開いています。汎用性の高い技術は、液体生検の可能性を最大限に引き出すための統合的なソリューションを提供することができます。

コンパニオン診断を使用する利点は、製薬会社や診断会社が負担する時間とコストを全体的に削減できることです。新規分子の開発と商業化に要する時間は、一般的に10年から15年です。診断と医薬品の共同開発により、規制当局の承認プロセスが促進され、コストが大幅に削減されます。2016年に治療とIVDコンパニオン診断の開発に関するFDAガイダンスドラフトが公表されて以来、多くのメーカーががん領域でのコンパニオン診断の開発を奨励しています。これは予測期間中の市場成長にプラスの影響を与えると予測されます。

がん診断市場のレポートハイライト

• 製品別では、消耗品セグメントが2024年に58.4%の最大シェアを占め、予測期間中に最も速い成長率が見込まれます。
• タイプ別では、体外診断（IVD）セグメントが2024年に52.0%のシェアを占めました。
• 乳がん用途セグメントは、国民全体に認識を広めるためのイニシアチブの増加や研究開発活動の増加により、予測期間中に大きく成長すると予想されています。
• 最終用途別では、効率的な外来患者サービスを提供する検査部門が市場を独占しています。病院セグメントは、入院患者の増加に起因して、今後数年間で著しい成長が予測されます。
• 生検セグメントは、疾患の早期発見を含む検査に伴う様々な利点により、大きな成長率で成長すると予測されています。
• 北米は、新しい診断検査の承認件数の増加により、2024年の世界がん診断市場を席巻しました。
• アジア太平洋は、有病率の上昇と主要参入企業の存在により、今後大幅な成長が見込まれます。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 市場の変数、動向、範囲

• 市場セグメンテーションと範囲
• 市場系統の展望
  • 親市場の展望
  • 関連/付随市場の展望
• 市場力学
• 市場促進要因
  • がん罹患率の上昇
  • 技術の進歩
  • 公的機関と民間組織による取り組みの増加
  • 新しい検査ソリューションの開発のための広範な研究開発
• 市場抑制要因分析
  • 診断画像にかかる高額な費用
  • 放射線被曝によりCTスキャンの使用が制限される可能性
  • 再生診断画像システムの採用増加
• ビジネス環境分析
  • SWOT分析、要因別（政治・法律、経済技術）
  • ポーターのファイブフォース分析
  • COVID-19の影響分析
• 市場機会分析
  • 個別化医療とコンパニオン診断の到来
• がん診断における人工知能の情勢
  • 市場動向：
  • 新製品開発
  • 主要参入企業とそのオファリング一覧
• 固形生検と液体生検の比較分析
• 血液ベースの診断の動向
• CfDNA検査の情勢
  • 承認された検査
  • 臨床検査の情勢
• NGS検査の情勢
• 早期発見の動向
  • 無症状患者の早期発見
  • 症状のある患者
  • 再発検出
• 米国のがん研究助成金の情勢
  • がんタイプ別
  • 状態別
• 特許出願の情勢
• 今後の技術が患者の治療経路にどのように適合するかについての定性分析

第4章 製品ビジネス分析

• がん診断市場：製品変動分析
• 装置
  • 装置市場、2018～2030年
  • 病理学ベースの機器
  • 画像機器
  • その他
• 消耗品
  • 消耗品市場、2018～2030年
• サービス
  • サービス市場、2018～2030年

第5章 タイプビジネス分析

• がん診断市場：タイプ変動分析
• 体外診断
  • IVD市場、2018～2030年
  • IVD市場、タイプ別2018～2030年
  • IVD市場、技術別2018～2030年
• LDDT
  • LDT市場、2018～2030年
• イメージング
  • イメージング市場、2018～2030年
  • 磁気共鳴画像（MRI）
  • コンピュータ断層撮影（CT）
  • 陽電子放出断層撮影（PET）
  • マンモグラフィー
  • 超音波
  • その他

第6章 用途ビジネス分析

• がん診断市場：用途変動分析
• 乳がん
  • 乳がん市場、2018～2030年
• 大腸がん
  • 大腸がん市場、2018～2030年
• 子宮頸がん
  • 子宮頸がん市場、2018～2030年
• 肺がん
  • 肺がん市場、2018～2030年
• 前立腺がん
  • 前立腺がん市場、2018～2030年
• 皮膚がん
  • 皮膚がん市場、2018～2030年
• 血液がん
  • 血液がん市場、2018～2030年
• 腎臓がん
  • 腎臓がん市場、2018～2030年
• 肝臓がん
  • 肝臓がん市場、2018～2030年
• 膵臓がん
  • 膵臓がん市場、2018～2030年
• 卵巣がん
  • 卵巣がん市場、2018～2030年
• その他
  • その他市場、2018～2030年

第7章 最終用途ビジネス分析

• がん診断市場：最終用途変動分析
• 病院
  • 病院市場、2018～2030年
• ラボ
  • ラボ市場、2018～2030年
• その他
  • その他のがん診断市場、2018～2030年

第8章 検査タイプビジネス分析

• がん診断市場：検査タイプ変動分析
• 生検
  • 生検市場、2018～2030年
  • 穿刺吸引法
  • コア生検
  • 外科的生検
  • 皮膚生検/パンチ生検
  • その他
• その他
  • その他のがん診断市場、2018～2030年

第9章 製品ビジネス分析

• がん診断市場：製品変動分析
• 装置
  • 装置市場、2018～2030年
• 消耗品キットと試薬
  • 消耗品キットと試薬市場、2018～2030年
• ソフトウェアとサービス
  • ソフトウェアとサービス市場、2018～2030年

第10章 対象範囲ビジネス分析

• がん診断市場：対象範囲変動分析
• 公的保険
  • 公的保険市場、2018～2030年
• 民間保険
  • 民間保険市場、2018～2030年

第11章 地域ビジネス分析

• 地域別がん診断市場シェア、2024年と2030年
• 北米
  • 北米のがん診断市場、2018～2030年
  • 米国
  • カナダ
• 欧州
  • 欧州のがん診断市場、2018～2030年
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • デンマーク
  • スウェーデン
  • ノルウェー
• アジア太平洋
  • アジア太平洋のがん診断市場、2018～2030年
  • 日本
  • 中国
  • インド
  • 韓国
  • オーストラリア
  • タイ
• ラテンアメリカ
  • ラテンアメリカのがん診断市場、2018～2030年
  • ブラジル
  • メキシコ
  • アルゼンチン
• 中東・アフリカ
  • 中東・アフリカがん診断市場、2018～2030年
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第12章 競合情勢

• 企業分類
• がん診断市場シェア分析、2024年
• 企業プロファイル
  • Abbott
  • Ge Healthcare
  • F. Hoffmann-la Roche Ltd.
  • Qiagen
  • Bd
  • Siemens Healthcare Gmbh
  • Thermo Fisher Scientific, Inc.
  • Hologic, Inc.
  • Koninklijke Philips Nv（Philips）
  • Illumina, Inc.
  • Agilent Technologies Inc
  • Foundation Medicine
  • Danaher Corporation
  • Bio-rad Laboratories, Inc
  • Perkinelmer Inc
  • Myriad Genetics, Inc.
  • Sysmex Corporation
  • Neogenomics Laboratories, Inc
  • Exact Sciences Corporation
  • Grail
  • Guardant Health Inc,.
  • Tempus
  • Delfi Diagnostics
  • Adela, Inc
  • Clearnote Health
  • Natera
• 戦略マッピング
  • 拡大
  • 取得
  • コラボレーション
  • 疾患タイプ/薬剤クラス発売
  • パートナーシップ
  • その他
• 大手企業向け流通モデル分析
• 2024年の米国がん診断市場の競争ヒートマップ分析
• 2024年の英国がん診断市場の競争ヒートマップ分析
• 原発不明がんの診断会社一覧
• ガーダント検査評価

第13章 結論/主要ポイント

List of Tables

• Table 1 List of abbreviations
• Table 2 Global cancer diagnostics market, by region, 2018 - 2030 (USD Billion)
• Table 3 Global cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 4 Global cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
• Table 5 Global cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
• Table 6 Global cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
• Table 7 Global cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
• Table 8 North America cancer diagnostics market, by country, 2018 - 2030 (USD Billion)
• Table 9 North America cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 10 North America cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
• Table 11 North America cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
• Table 12 North America cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
• Table 13 North America cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
• Table 14 North America cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
• Table 15 U.S. cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 16 U.S. cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
• Table 17 U.S. cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
• Table 18 U.S. cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
• Table 19 U.S. cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
• Table 20 U.S. cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
• Table 21 Canada cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 22 Canada cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
• Table 23 Canada cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
• Table 24 Canada cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
• Table 25 Canada cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
• Table 26 Canada cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
• Table 27 Europe cancer diagnostics market, by country, 2018 - 2030 (USD Billion)
• Table 28 Europe cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 29 Europe cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
• Table 30 Europe cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
• Table 31 Europe cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
• Table 32 Europe cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
• Table 33 Europe cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
• Table 34 UK cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 35 UK cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
• Table 36 UK cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
• Table 37 UK cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
• Table 38 UK cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
• Table 39 UK cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
• Table 40 Germany cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 41 Germany cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
• Table 42 Germany cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
• Table 43 Germany cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
• Table 44 Germany cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
• Table 45 Germany cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
• Table 46 France cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 47 France cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
• Table 48 France cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
• Table 49 France cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
• Table 50 France cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
• Table 51 France cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
• Table 52 Italy cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 53 Italy cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
• Table 54 Italy cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
• Table 55 Italy cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
• Table 56 Italy cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
• Table 57 Italy cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
• Table 58 Spain cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 59 Spain cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
• Table 60 Spain cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
• Table 61 Spain cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
• Table 62 Spain cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
• Table 63 Spain cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
• Table 64 Denmark cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 65 Denmark cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
• Table 66 Denmark cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
• Table 67 Denmark cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
• Table 68 Denmark cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
• Table 69 Denmark cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
• Table 70 Sweden cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 71 Sweden cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
• Table 72 Sweden cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
• Table 73 Sweden cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
• Table 74 Sweden cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
• Table 75 Sweden cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
• Table 76 Norway cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 77 Norway cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
• Table 78 Norway cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
• Table 79 Norway cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
• Table 80 Norway cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
• Table 81 Norway cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
• Table 82 Asia Pacific cancer diagnostics market, by country, 2018 - 2030 (USD Billion)
• Table 83 Asia Pacific cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 84 Asia Pacific cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
• Table 85 Asia Pacific cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
• Table 86 Asia Pacific cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
• Table 87 Asia Pacific cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
• Table 88 Asia Pacific cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
• Table 89 Japan cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 90 Japan cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
• Table 91 Japan cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
• Table 92 Japan cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
• Table 93 Japan cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
• Table 94 Japan cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
• Table 95 China cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 96 China cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
• Table 97 China cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
• Table 98 China cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
• Table 99 China cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
• Table 100 China cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
• Table 101 India cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 102 India cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
• Table 103 India cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
• Table 104 India cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
• Table 105 India cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
• Table 106 India cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
• Table 107 South Korea cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 108 South Korea cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
• Table 109 South Korea cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
• Table 110 South Korea cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
• Table 111 South Korea cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
• Table 112 South Korea cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
• Table 113 Thailand cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 114 Thailand cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
• Table 115 Thailand cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
• Table 116 Thailand cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
• Table 117 Thailand cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
• Table 118 Thailand cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
• Table 119 Australia cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 120 Australia cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
• Table 121 Australia cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
• Table 122 Australia cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
• Table 123 Australia cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
• Table 124 Australia cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
• Table 125 Latin America cancer diagnostics market, by country, 2018 - 2030 (USD Billion)
• Table 126 Latin America cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 127 Latin America cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
• Table 128 Latin America cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
• Table 129 Latin America cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
• Table 130 Latin America cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
• Table 131 Latin America cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
• Table 132 Brazil cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 133 Brazil cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
• Table 134 Brazil cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
• Table 135 Brazil cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
• Table 136 Brazil cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
• Table 137 Brazil cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
• Table 138 Mexico cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 139 Mexico cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
• Table 140 Mexico cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
• Table 141 Mexico cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
• Table 142 Mexico cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
• Table 143 Mexico cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
• Table 144 Argentina cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 145 Argentina cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
• Table 146 Argentina cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
• Table 147 Argentina cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
• Table 148 Argentina cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
• Table 149 Argentina cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
• Table 150 Middle East & Africa cancer diagnostics market, by country, 2018 - 2030 (USD Billion)
• Table 151 Middle East & Africa cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 152 Middle East & Africa cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
• Table 153 Middle East & Africa cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
• Table 154 Middle East & Africa cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
• Table 155 Middle East & Africa cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
• Table 156 Middle East & Africa cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
• Table 157 South Africa cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 158 South Africa cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
• Table 159 South Africa cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
• Table 160 South Africa cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
• Table 161 South Africa cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
• Table 162 South Africa cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
• Table 163 Saudi Arabia cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 164 Saudi Arabia cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
• Table 165 Saudi Arabia cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
• Table 166 Saudi Arabia cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
• Table 167 Saudi Arabia cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
• Table 168 Saudi Arabia cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
• Table 169 UAE cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 170 UAE cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
• Table 171 UAE cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
• Table 172 UAE cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
• Table 173 UAE cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
• Table 174 UAE cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)
• Table 175 Kuwait cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 176 Kuwait cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
• Table 177 Kuwait cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
• Table 178 Kuwait cancer diagnostics market, by end use, 2018 - 2030 (USD Billion)
• Table 179 Kuwait cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
• Table 180 Kuwait cancer diagnostics market, by coverage, 2018 - 2030 (USD Billion)

List of Figures

• Fig. 1 Cancer diagnostics market segmentation
• Fig. 2 Market research process
• Fig. 3 Information procurement
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value chain based sizing & forecasting
• Fig. 7 QFD modelling for market share assessment
• Fig. 8 Market formulation & validation
• Fig. 9 Market snapshot
• Fig. 10 Product and type segment snapshot
• Fig. 11 Application segment snapshot
• Fig. 12 End use and test type segment snapshot
• Fig. 13 Competitive landscape snapshot
• Fig. 14 Cancer diagnostics market value, 2024 (USD Billion)
• Fig. 15 Market dynamics
• Fig. 16 Incidence of most common cancers globally, 2024
• Fig. 17 Porter's five forces analysis
• Fig. 18 PESTLE analysis
• Fig. 19 Cancer diagnostics market: Product outlook and key takeaways
• Fig. 20 Cancer diagnostics market: Product movement analysis
• Fig. 21 Instruments market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 22 Pathology-based instruments market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 23 Slide staining systems market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 24 Tissue processing systems market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 25 Cell processors market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 26 PCR instruments market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 27 NGS instruments market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 28 Microarrays market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 29 Other pathology-based instruments market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 30 Imaging instruments market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 31 Others market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 32 Consumables market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 33 Antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 34 Kits & reagents market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 35 Probes market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 36 Others market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 37 Services market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 38 Cancer diagnostics market: Type outlook and key takeaways
• Fig. 39 Cancer diagnostics market: Type movement analysis
• Fig. 40 IVD market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 41 Diagnosis market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 42 Early detection market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 43 Therapy selection market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 44 Monitoring market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 45 Polymerase Chain Reaction (PCR) market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 46 In Situ Hybridization (ISH) market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 47 Immunohistochemistry (IHC) market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 48 Next-generation Sequencing (NGS) market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 49 Microarrays market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 50 Flow cytometry market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 51 Immunoassays market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 52 Other IVD testing technologies market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 53 LDT market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 54 Imaging market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 55 Magnetic Resonance Imaging (MRI) market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 56 Computed Tomography (CT) market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 57 Positron Emission Tomography (PET) market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 58 Mammography market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 59 Ultrasound market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 60 Others market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 61 Cancer diagnostics market: Application outlook and key takeaways
• Fig. 62 Cancer diagnostics market: Application movement analysis
• Fig. 63 Breast cancer market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 64 Colorectal cancer market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 65 Cervical cancer market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 66 Lung cancer market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 67 Prostate cancer market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 68 Skin cancer market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 69 Blood cancer market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 70 Kidney cancer market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 71 Liver cancer market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 72 Pancreatic cancer market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 73 Ovarian cancer market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 74 Others market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 75 Cancer diagnostics market: End use outlook and key takeaways
• Fig. 76 Cancer diagnostics market: End use movement analysis
• Fig. 77 Hospitals market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 78 Laboratories market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 79 Others market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 80 Cancer diagnostics market: Test type outlook and key takeaways
• Fig. 81 Cancer diagnostics market: Test type movement analysis
• Fig. 82 Biopsy market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 83 Fine-needle aspiration market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 84 Core biopsy market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 85 Surgical biopsy market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 86 Skin biopsy/punch biopsy market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 87 Others market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 88 Others market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 89 Cancer diagnostics market: Coverage outlook and key takeaways
• Fig. 90 Cancer diagnostics market: Coverage movement analysis
• Fig. 91 Public insurance market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 92 Private insurance market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 93 Cancer Diagnostics Market revenue, by region, 2024 & 2030 (USD Billion)
• Fig. 94 Regional marketplace: Key takeaways
• Fig. 95 Regional marketplace: Key takeaways
• Fig. 96 North America cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 97 Key country dynamics
• Fig. 98 U.S. cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 99 Cancer incidence, 2018 - 2030
• Fig. 100 Ways to obtain coverage
• Fig. 101 Key country dynamics
• Fig. 102 Canada cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 103 Cancer incidence, 2018 - 2030
• Fig. 104 Europe cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 105 Key country dynamics
• Fig. 106 UK cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 107 Cancer incidence, 2018 - 2030
• Fig. 108 Key country dynamics
• Fig. 109 Germany cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 110 Cancer incidence, 2018 - 2030
• Fig. 111 Key country dynamics
• Fig. 112 France cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 113 Cancer incidence, 2018 - 2030
• Fig. 114 Key country dynamics
• Fig. 115 Spain cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 116 Cancer incidence, 2018 - 2030
• Fig. 117 Key country dynamics
• Fig. 118 Italy cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 119 Cancer incidence, 2018 - 2030
• Fig. 120 Key country dynamics
• Fig. 121 Denmark cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 122 Target disease prevalence
• Fig. 123 Key country dynamics
• Fig. 124 Sweden cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 125 Five most common cancers in Sweden
• Fig. 126 Key country dynamics
• Fig. 127 Norway cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 128 Number of new cancer cases in 2020, both sexes, all ages
• Fig. 129 Rest of Europe cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 130 Asia Pacific cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 131 Key country dynamics
• Fig. 132 Japan cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 133 Cancer incidence, 2018 to 2030
• Fig. 134 Key country dynamics
• Fig. 135 China cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 136 Cancer incidence, 2018 to 2030
• Fig. 137 China regulatory details
• Fig. 138 Key country dynamics
• Fig. 139 India cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 140 Cancer incidence, 2018 to 2030
• Fig. 141 Key country dynamics
• Fig. 142 Australia cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 143 Cancer incidence, 2018 to 2030
• Fig. 144 Key country dynamics
• Fig. 145 Thailand cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 146 Cancer incidence, 2020 to 2030
• Fig. 147 Key country dynamics
• Fig. 148 South Korea cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 149 Cancer incidence 2018 to 2030
• Fig. 150 South Korean regulations in four hierarchical orders
• Fig. 151 South Korea reimbursement scenario
• Fig. 152 Rest of Asia Pacific cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 153 Latin America cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 154 Key country dynamics
• Fig. 155 Brazil cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 156 Estimated number of new cancer cases in Brazil
• Fig. 157 Key country dynamics
• Fig. 158 Mexico cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 159 Estimated number of new cancer cases in Mexico
• Fig. 160 Key country dynamics
• Fig. 161 Argentina cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 162 Estimated number of new cancer cases in Argentina
• Fig. 163 Rest of Latin America cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 164 MEA cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 165 Key country dynamics
• Fig. 166 South Africa cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 167 Cancer prevalence-2018 - 2030
• Fig. 168 Key country dynamics
• Fig. 169 Saudi Arabia cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 170 Cancer prevalence-2018 - 2030
• Fig. 171 Key country dynamics
• Fig. 172 UAE cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 173 Cancer prevalence 2018 - 2030
• Fig. 174 Key country dynamics
• Fig. 175 Kuwait cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 176 Target disease prevalence
• Fig. 177 Key payers in Kuwait
• Fig. 178 Rest of MEA cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 179 Key company categorization
• Fig. 180 Company market share analysis, 2024
• Fig. 181 Strategic framework
• Fig. 182 Competitive heat map analysis for U.S.
• Fig. 183 Competitive heat map analysis for UK

Cancer Diagnostics Market Growth & Trends:

The global cancer diagnostics market size is anticipated to reach USD 155.07 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 6.14% from 2025 to 2030. Increasing number of programs to raise awareness about cancer by several organizations is a major factor accountable for increased demand for diagnostic products worldwide. Partnerships and collaborations undertaken by the National Cervical Cancer Coalition, WHO, CDC, the U.S. Preventive Services Task Force, & others for increasing cervical cancer screening are among the major factors expected to boost market growth during the forecast period.

Several countries have thus undertaken measures to increase screening for early diagnosis and help existing patients. For instance, Ayushman Bharat and the Prime Minister's National Relief Fund was initiated by the Indian government for patients who require assistance during the treatment. Similarly, the Indian government's Department of Biotechnology signed a contract with Cancer Research UK to conduct research for affordable approaches to diagnosis and treatment.

Liquid biopsy solutions are being increasingly adopted as MCED tests as they are easily accessible for clinical applications. In recent years, they have gained regulatory approval with comprehensive and multi-cancer diagnostic approaches. Breakthrough advancements in the field and ongoing studies for early detection are contributing to market growth. Moreover, technologies such as circulating tumor DNA, extracellular vesicles, and circulating tumor cells are paving the way for better cancer care. Versatile technologies can provide integrated solutions for maximizing the potential of liquid biopsy.

Advantage of using companion diagnostics is the overall reduction in time and costs incurred by pharmaceutical and diagnostic companies. The time required to develop and commercialize a novel molecule generally consists of 10 to 15 years. Co-development of diagnostics and drugs facilitates accelerated regulatory approval processes, which significantly reduces costs. . Since the FDA guidance draft for the development of an IVD companion diagnostic device with a therapeutic product was published in 2016, many manufacturers encourage the development of companion diagnostic assays in the field of oncology. This is anticipated to positively impact market growth during the forecast period.

Cancer Diagnostics Market Report Highlights:

• Based on product, the consumables segment held the largest share of 58.4% in 2024 and is anticipated to grow at the fastest growth rate over the forecast period
• Based on type, in vitro diagnostics (IVD) segment dominated the in 2024 with a share of 52.0% due to the increasing adoption of IVD owing to the rise in testing amid COVID-19 pandemic.
• The breast cancer application segment is expected to grow lucratively over the forecast period due to growth in initiatives to spread awareness across the population and increase in R&D activities.
• Based on end-use, the laboratories segment dominated the market due to efficient outpatient services. The hospitals segment is forecasted grow at a significant rate over the coming years attributed to an increase in the admittance of patients in hospitals
• The biopsy segment is anticipated to grow at a significant growth rate due to various benefits associated with the test, including early detection of the disease
• North America dominated the global cancer diagnostics market in 2024, owing to rise in the number of approvals of new diagnostic tests
• The Asia Pacific is expected to grow considerably in the future owing to due to the rising prevalence and the presence of key players

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation
  • 1.1.1. Market Definitions
• 1.2. Objectives
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information Or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
• 1.8. List Of Secondary Sources
• 1.9. List Of Abbreviations
• 1.10. List Of Primary Sources

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Product And Type Snapshot
• 2.3. Application And End Use Snapshot
• 2.4. Test Type And Coveragesnapshot
• 2.5. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Segmentation And Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/ancillary Market Outlook
• 3.3. Market Dynamics
• 3.4. Market Drivers
  • 3.4.1. Rising Prevalence Of Cancer
  • 3.4.2. Technological Advancements
  • 3.4.3. Rising Initiatives Undertaken By Public And Private Organizations
  • 3.4.4. Extensive R&d For The Development Of Novel Testing Solutions
• 3.5. Market Restraint Analysis
  • 3.5.1. High Cost Of Diagnostic Imaging
  • 3.5.2. Radiation Exposure Likely To Limit Usage Of Ct Scans
  • 3.5.3. Rising Adoption Of Refurbished Diagnostic Imaging Systems
• 3.6. Business Environment Analysis
  • 3.6.1. Swot Analysis; By Factor (Political & Legal, Economic And Technological)
  • 3.6.2. Porter's Five Forces Analysis
  • 3.6.3. Covid-19 Impact Analysis
• 3.7. Market Opportunity Analysis
  • 3.7.1. Advent Of Personalized Medicine And Companion Diagnostics
• 3.8. Artificial Intelligence Landscape For Cancer Diagnostics
  • 3.8.1. Market Trends:
  • 3.8.2. New Product Development
  • 3.8.3. List Of Key Players With Their Offerings
• 3.9. Comparative Analysis Of Solid Vs. Liquid Biopsies
• 3.10. Trends In Blood-based Diagnostics
• 3.11. Cfdna Test Landscape
  • 3.11.1. Approved Tests
  • 3.11.2. Clinical Trials Landscape
• 3.12. Ngs Tests Landscape
• 3.13. Trends In Early Detection
  • 3.13.1. Early Detection In Asymptomatic Patients
  • 3.13.2. Symptomatic Patients
  • 3.13.3. Recurrence Detection
• 3.14. U.S. Cancer Research Grants Funding Landscape
  • 3.14.1. By Cancer Type
  • 3.14.2. By State
• 3.15. Patent Filing Landscape
• 3.16. Qualitative Analysis Of How Upcoming Technologies Fit Into Patient Pathways

Chapter 4. Product Business Analysis

• 4.1. Cancer Diagnostics Market: Product Movement Analysis
• 4.2. Instruments
  • 4.2.1. Instruments Market, 2018 - 2030 (USD Billion)
  • 4.2.2. Pathology Based-instruments
    • 4.2.2.1. Slide Staining Systems
      • 4.2.2.1.1. Slide Staining Systems Market, 2018 - 2030 (USD Billion)
    • 4.2.2.2. Tissue Processing Systems
      • 4.2.2.2.1. Tissue Processing Systems Market, 2018 - 2030 (USD Billion)
    • 4.2.2.3. Cell Processors
      • 4.2.2.3.1. Cell Processors Systems Market, 2018 - 2030 (USD Billion)
    • 4.2.2.4. Pcr Instruments
      • 4.2.2.4.1. Pcr Instruments Market, 2018 - 2030 (USD Billion)
    • 4.2.2.5. Ngs Instruments
      • 4.2.2.5.1. Ngs Instruments Market, 2018 - 2030 (USD Billion)
    • 4.2.2.6. Microarrays
      • 4.2.2.6.1. Microarrays Market, 2018 - 2030 (USD Billion)
    • 4.2.2.7. Other Pathology-based Instruments
      • 4.2.2.7.1. Other Pathology-based Instruments Market, 2018 - 2030 (USD Billion)
  • 4.2.3. Imaging Instruments
  • 4.2.4. Others
• 4.3. Consumables
  • 4.3.1. Consumables Market, 2018 - 2030 (USD Billion)
• 4.4. Services
  • 4.4.1. Services Market, 2018 - 2030 (USD Billion)

Chapter 5. Type Business Analysis

• 5.1. Cancer Diagnostics Market: Type Movement Analysis
• 5.2. IVD
  • 5.2.1. IVD Market, 2018 - 2030 (USD Billion)
  • 5.2.2. IVD Market, By Type 2018 - 2030 (USD Billion)
    • 5.2.2.1. Diagnosis
      • 5.2.2.1.1. Diagnosis Market, 2018 - 2030 (USD Billion)
    • 5.2.2.2. Early Detection
      • 5.2.2.2.1. Early Detection Market, 2018 - 2030 (USD Billion)
    • 5.2.2.3. Therapy Selection
      • 5.2.2.3.1. Therapy Selection Market, 2018 - 2030 (USD Billion)
    • 5.2.2.4. Monitoring
      • 5.2.2.4.1. Monitoring Market, 2018 - 2030 (USD Billion)
  • 5.2.3. IVD Market, By Technology 2018 - 2030 (USD Billion)
    • 5.2.3.1. Polymerase Chain Reaction (Pcr)
      • 5.2.3.1.1. Polymerase Chain Reaction (Pcr) Market, 2018 - 2030 (USD Billion)
    • 5.2.3.2. In Situ Hybridization (Ish)
      • 5.2.3.2.1. In Situ Hybridization (Ish) Market, 2018 - 2030 (USD Billion)
    • 5.2.3.3. Immunohistochemistry (Ihc)
      • 5.2.3.3.1. Immunohistochemistry (Ihc) Market, 2018 - 2030 (USD Billion)
    • 5.2.3.4. Next-generation Sequencing (Ngs)
      • 5.2.3.4.1. Next-generation Sequencing (Ngs) Market, 2018 - 2030 (USD Billion)
    • 5.2.3.5. Microarrays
      • 5.2.3.5.1. Microarrays Market, 2018 - 2030 (USD Billion)
    • 5.2.3.6. Flow Cytometry
      • 5.2.3.6.1. Flow Cytometry Market, 2018 - 2030 (USD Billion)
    • 5.2.3.7. Immunoassays
      • 5.2.3.7.1. Immunoassays Market, 2018 - 2030 (USD Billion)
    • 5.2.3.8. Other IVD Testing Technologies
      • 5.2.3.8.1. Other IVD Testing Technologies Market, 2018 - 2030 (USD Billion)
• 5.3. LDT
  • 5.3.1. LDT Market, 2018 - 2030 (USD Billion)
• 5.4. Imaging
  • 5.4.1. Imaging Market, 2018 - 2030 (USD Billion)
  • 5.4.2. Magnetic Resonance Imaging (Mri)
    • 5.4.2.1. Magnetic Resonance Imaging (Mri) Market, 2018 - 2030 (USD Billion)
  • 5.4.3. Computed Tomography (Ct)
    • 5.4.3.1. Computed Tomography (Ct) Market, 2018 - 2030 (USD Billion)
  • 5.4.4. Positron Emission Tomography (Pet)
    • 5.4.4.1. Positron Emission Tomography (Pet) Market, 2018 - 2030 (USD Billion)
  • 5.4.5. Mammography
    • 5.4.5.1. Mammography Market, 2018 - 2030 (USD Billion)
  • 5.4.6. Ultrasound
    • 5.4.6.1. Ultrasound Market, 2018 - 2030 (USD Billion)
  • 5.4.7. Others
    • 5.4.7.1. Others Market, 2018 - 2030 (USD Billion)

Chapter 6. Application Business Analysis

• 6.1. Cancer Diagnostics Market: Application Movement Analysis
• 6.2. Breast Cancer
  • 6.2.1. Breast Cancer Market, 2018 - 2030 (USD Billion)
• 6.3. Colorectal Cancer
  • 6.3.1. Colorectal Cancer Market, 2018 - 2030 (USD Billion)
• 6.4. Cervical Cancer
  • 6.4.1. Cervical Cancer Market, 2018 - 2030 (USD Billion)
• 6.5. Lung Cancer
  • 6.5.1. Lung Cancer Market, 2018 - 2030 (USD Billion)
• 6.6. Prostate Cancer
  • 6.6.1. Prostate Cancer Market, 2018 - 2030 (USD Billion)
• 6.7. Skin Cancer
  • 6.7.1. Skin Cancer Market, 2018 - 2030 (USD Billion)
• 6.8. Blood Cancer
  • 6.8.1. Blood Cancer Market, 2018 - 2030 (USD Billion)
• 6.9. Kidney Cancer
  • 6.9.1. Kidney Cancer Market, 2018 - 2030 (USD Billion)
• 6.10. Liver Cancer
  • 6.10.1. Liver Cancer Market, 2018 - 2030 (USD Billion)
• 6.11. Pancreatic Cancer
  • 6.11.1. Pancreatic Cancer Market, 2018 - 2030 (USD Billion)
• 6.12. Ovarian Cancer
  • 6.12.1. Ovarian Cancer Market, 2018 - 2030 (USD Billion)
• 6.13. Others
  • 6.13.1. Others Market, 2018 - 2030 (USD Billion)

Chapter 7. End Use Business Analysis

• 7.1. Cancer Diagnostics Market: End Use Movement Analysis
• 7.2. Hospitals
  • 7.2.1. Hospitals Market, 2018 - 2030 (USD Billion)
• 7.3. Laboratories
  • 7.3.1. Laboratories Market, 2018 - 2030 (USD Billion)
• 7.4. Others
  • 7.4.1. Others Cancer Diagnostics Market, 2018 - 2030 (USD Billion)

Chapter 8. Test Type Business Analysis

• 8.1. Cancer Diagnostics Market: Test Type Movement Analysis
• 8.2. Biopsy
  • 8.2.1. Biopsy Market, 2018 - 2030 (USD Billion)
  • 8.2.2. Fine-needle Aspiration
    • 8.2.2.1. Fine-needle Aspiration Market, 2018 - 2030 (USD Billion)
  • 8.2.3. Core Biopsy
    • 8.2.3.1. Core Biopsy Market, 2018 - 2030 (USD Billion)
  • 8.2.4. Surgical Biopsy
    • 8.2.4.1. Surgical Biopsy Market, 2018 - 2030 (USD Billion)
  • 8.2.5. Skin Biopsy /punch Biopsy
    • 8.2.5.1. Skin Biopsy /punch Biopsy Market, 2018 - 2030 (USD Billion)
  • 8.2.6. Others
    • 8.2.6.1. Others Market, 2018 - 2030 (USD Billion)
• 8.3. Others
  • 8.3.1. Others Cancer Diagnostics Market, 2018 - 2030 (USD Billion)

Chapter 9. Product Business Analysis

• 9.1. Cancer Diagnostics Market: Product Movement Analysis
• 9.2. Instruments
  • 9.2.1. Instruments Market, 2018 - 2030 (USD Billion)
• 9.3. Consumables Kits And Reagents
  • 9.3.1. Consumables Kits And Reagents Market, 2018 - 2030 (USD Billion)
• 9.4. Software And Services
  • 9.4.1. Software And Services Market, 2018 - 2030 (USD Billion)

Chapter 10. Coverage Business Analysis

• 10.1. Cancer Diagnostics Market: Coverage Movement Analysis
• 10.2. Public Insurance
  • 10.2.1. Public Insurance Market, 2018 - 2030 (USD Billion)
• 10.3. Private Insurance
  • 10.3.1. Private Insurance Market, 2018 - 2030 (USD Billion)

Chapter 11. Regional Business Analysis

• 11.1. Cancer Diagnostics Market Share By Region, 2024 & 2030
• 11.2. North America
  • 11.2.1. North America Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
  • 11.2.2. U.S.
    • 11.2.2.1. Key Country Dynamics
    • 11.2.2.2. Target Disease Prevalence
    • 11.2.2.3. Competitive Scenario
    • 11.2.2.4. Regulatory Framework
    • 11.2.2.5. Reimbursement Scenario
    • 11.2.2.6. U.S. Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
  • 11.2.3. Canada
    • 11.2.3.1. Key Country Dynamics
    • 11.2.3.2. Target Disease Prevalence
    • 11.2.3.3. Competitive Scenario
    • 11.2.3.4. Regulatory Framework
    • 11.2.3.5. Reimbursement Scenario
    • 11.2.3.6. Canada Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
• 11.3. Europe
  • 11.3.1. Europe Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
  • 11.3.2. Germany
    • 11.3.2.1. Key Country Dynamics
    • 11.3.2.2. Target Disease Prevalence
    • 11.3.2.3. Competitive Scenario
    • 11.3.2.4. Regulatory Framework
    • 11.3.2.5. Reimbursement Scenario
    • 11.3.2.6. Germany Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
  • 11.3.3. Uk
    • 11.3.3.1. Key Country Dynamics
    • 11.3.3.2. Target Disease Prevalence
    • 11.3.3.3. Competitive Scenario
    • 11.3.3.4. Regulatory Framework
    • 11.3.3.5. Reimbursement Scenario
    • 11.3.3.6. Uk Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
  • 11.3.4. France
    • 11.3.4.1. Key Country Dynamics
    • 11.3.4.2. Target Disease Prevalence
    • 11.3.4.3. Competitive Scenario
    • 11.3.4.4. Regulatory Framework
    • 11.3.4.5. Reimbursement Scenario
    • 11.3.4.6. France Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
  • 11.3.5. Italy
    • 11.3.5.1. Key Country Dynamics
    • 11.3.5.2. Target Disease Prevalence
    • 11.3.5.3. Competitive Scenario
    • 11.3.5.4. Regulatory Framework
    • 11.3.5.5. Reimbursement Scenario
    • 11.3.5.6. Italy Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
  • 11.3.6. Spain
    • 11.3.6.1. Key Country Dynamics
    • 11.3.6.2. Target Disease Prevalence
    • 11.3.6.3. Competitive Scenario
    • 11.3.6.4. Regulatory Framework
    • 11.3.6.5. Reimbursement Scenario
    • 11.3.6.6. Spain Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
  • 11.3.7. Denmark
    • 11.3.7.1. Key Country Dynamics
    • 11.3.7.2. Target Disease Prevalence
    • 11.3.7.3. Competitive Scenario
    • 11.3.7.4. Regulatory Framework
    • 11.3.7.5. Reimbursement Scenario
    • 11.3.7.6. Denmark Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
  • 11.3.8. Sweden
    • 11.3.8.1. Key Country Dynamics
    • 11.3.8.2. Target Disease Prevalence
    • 11.3.8.3. Competitive Scenario
    • 11.3.8.4. Regulatory Framework
    • 11.3.8.5. Reimbursement Scenario
    • 11.3.8.6. Sweden Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
  • 11.3.9. Norway
    • 11.3.9.1. Key Country Dynamics
    • 11.3.9.2. Target Disease Prevalence
    • 11.3.9.3. Competitive Scenario
    • 11.3.9.4. Regulatory Framework
    • 11.3.9.5. Reimbursement Scenario
    • 11.3.9.6. Norway Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
• 11.4. Asia Pacific
  • 11.4.1. Asia Pacific Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
  • 11.4.2. Japan
    • 11.4.2.1. Key Country Dynamics
    • 11.4.2.2. Target Disease Prevalence
    • 11.4.2.3. Competitive Scenario
    • 11.4.2.4. Regulatory Framework
    • 11.4.2.5. Reimbursement Scenario
    • 11.4.2.6. Japan Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
  • 11.4.3. China
    • 11.4.3.1. Key Country Dynamics
    • 11.4.3.2. Target Disease Prevalence
    • 11.4.3.3. Competitive Scenario
    • 11.4.3.4. Regulatory Framework
    • 11.4.3.5. Reimbursement Scenario
    • 11.4.3.6. China Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
  • 11.4.4. India
    • 11.4.4.1. Key Country Dynamics
    • 11.4.4.2. Target Disease Prevalence
    • 11.4.4.3. Competitive Scenario
    • 11.4.4.4. Regulatory Framework
    • 11.4.4.5. Reimbursement Scenario
    • 11.4.4.6. India Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
  • 11.4.5. South Korea
    • 11.4.5.1. Key Country Dynamics
    • 11.4.5.2. Target Disease Prevalence
    • 11.4.5.3. Competitive Scenario
    • 11.4.5.4. Regulatory Framework
    • 11.4.5.5. Reimbursement Scenario
    • 11.4.5.6. South Korea Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
  • 11.4.6. Australia
    • 11.4.6.1. Key Country Dynamics
    • 11.4.6.2. Target Disease Prevalence
    • 11.4.6.3. Competitive Scenario
    • 11.4.6.4. Regulatory Framework
    • 11.4.6.5. Reimbursement Scenario
    • 11.4.6.6. Australia Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
  • 11.4.7. Thailand
    • 11.4.7.1. Key Country Dynamics
    • 11.4.7.2. Target Disease Prevalence
    • 11.4.7.3. Competitive Scenario
    • 11.4.7.4. Regulatory Framework
    • 11.4.7.5. Reimbursement Scenario
    • 11.4.7.6. Thailand Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
• 11.5. Latin America
  • 11.5.1. Latin America Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
  • 11.5.2. Brazil
    • 11.5.2.1. Key Country Dynamics
    • 11.5.2.2. Target Disease Prevalence
    • 11.5.2.3. Competitive Scenario
    • 11.5.2.4. Regulatory Framework
    • 11.5.2.5. Reimbursement Scenario
    • 11.5.2.6. Brazil Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
  • 11.5.3. Mexico
    • 11.5.3.1. Key Country Dynamics
    • 11.5.3.2. Target Disease Prevalence
    • 11.5.3.3. Competitive Scenario
    • 11.5.3.4. Regulatory Framework
    • 11.5.3.5. Reimbursement Scenario
    • 11.5.3.6. Mexico Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
  • 11.5.4. Argentina
    • 11.5.4.1. Key Country Dynamics
    • 11.5.4.2. Target Disease Prevalence
    • 11.5.4.3. Competitive Scenario
    • 11.5.4.4. Regulatory Framework
    • 11.5.4.5. Reimbursement Scenario
    • 11.5.4.6. Argentina Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
• 11.6. Mea
  • 11.6.1. Mea Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
  • 11.6.2. South Africa
    • 11.6.2.1. Key Country Dynamics
    • 11.6.2.2. Target Disease Prevalence
    • 11.6.2.3. Competitive Scenario
    • 11.6.2.4. Regulatory Framework
    • 11.6.2.5. Reimbursement Scenario
    • 11.6.2.6. South Africa Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
  • 11.6.3. Saudi Arabia
    • 11.6.3.1. Key Country Dynamics
    • 11.6.3.2. Target Disease Prevalence
    • 11.6.3.3. Competitive Scenario
    • 11.6.3.4. Regulatory Framework
    • 11.6.3.5. Reimbursement Scenario
    • 11.6.3.6. Saudi Arabia Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
  • 11.6.4. Uae
    • 11.6.4.1. Key Country Dynamics
    • 11.6.4.2. Target Disease Prevalence
    • 11.6.4.3. Competitive Scenario
    • 11.6.4.4. Regulatory Framework
    • 11.6.4.5. Reimbursement Scenario
    • 11.6.4.6. Uae Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
  • 11.6.5. Kuwait
    • 11.6.5.1. Key Country Dynamics
    • 11.6.5.2. Target Disease Prevalence
    • 11.6.5.3. Competitive Scenario
    • 11.6.5.4. Regulatory Framework
    • 11.6.5.5. Reimbursement Scenario
    • 11.6.5.6. Kuwait Cancer Diagnostics Market, 2018 - 2030 (USD Billion)

Chapter 12. Competitive Landscape

• 12.1. Company Categorization
• 12.2. Cancer Diagnostics Market Share Analysis, 2024
• 12.3. Company Profiles
  • 12.3.1. Abbott
    • 12.3.1.1. Company Overview
    • 12.3.1.2. Financial Performance
    • 12.3.1.3. Product Benchmarking
    • 12.3.1.4. Strategic Initiatives
  • 12.3.2. Ge Healthcare
    • 12.3.2.1. Company Overview
    • 12.3.2.2. Financial Performance
    • 12.3.2.3. Product Benchmarking
    • 12.3.2.4. Strategic Initiatives
  • 12.3.3. F. Hoffmann-la Roche Ltd.
    • 12.3.3.1. Company Overview
    • 12.3.3.2. Financial Performance
    • 12.3.3.3. Product Benchmarking
    • 12.3.3.4. Strategic Initiatives
  • 12.3.4. Qiagen
    • 12.3.4.1. Company Overview
    • 12.3.4.2. Financial Performance
    • 12.3.4.3. Product Benchmarking
    • 12.3.4.4. Strategic Initiatives
  • 12.3.5. Bd
    • 12.3.5.1. Company Overview
    • 12.3.5.2. Financial Performance
    • 12.3.5.3. Product Benchmarking
    • 12.3.5.4. Strategic Initiatives
  • 12.3.6. Siemens Healthcare Gmbh
    • 12.3.6.1. Company Overview
    • 12.3.6.2. Financial Performance
    • 12.3.6.3. Product Benchmarking
    • 12.3.6.4. Strategic Initiatives
  • 12.3.7. Thermo Fisher Scientific, Inc.
    • 12.3.7.1. Company Overview
    • 12.3.7.2. Financial Performance
    • 12.3.7.3. Product Benchmarking
    • 12.3.7.4. Strategic Initiatives
  • 12.3.8. Hologic, Inc.
    • 12.3.8.1. Company Overview
    • 12.3.8.2. Financial Performance
    • 12.3.8.3. Product Benchmarking
    • 12.3.8.4. Strategic Initiatives
  • 12.3.9. Koninklijke Philips N.v. (Philips)
    • 12.3.9.1. Company Overview
    • 12.3.9.2. Financial Performance
    • 12.3.9.3. Product Benchmarking
    • 12.3.9.4. Strategic Initiatives
  • 12.3.10. Illumina, Inc.
    • 12.3.10.1. Company Overview
    • 12.3.10.2. Financial Performance
    • 12.3.10.3. Product Benchmarking
    • 12.3.10.4. Strategic Initiatives
  • 12.3.11. Agilent Technologies Inc
    • 12.3.11.1. Company Overview
    • 12.3.11.2. Financial Performance
    • 12.3.11.3. Product Benchmarking
    • 12.3.11.4. Strategic Initiatives
  • 12.3.12. Foundation Medicine
    • 12.3.12.1. Company Overview
    • 12.3.12.2. Financial Performance
    • 12.3.12.3. Product Benchmarking
    • 12.3.12.4. Strategic Initiatives
  • 12.3.13. Danaher Corporation
    • 12.3.13.1. Company Overview
    • 12.3.13.2. Financial Performance
    • 12.3.13.3. Product Benchmarking
    • 12.3.13.4. Strategic Initiatives
  • 12.3.14. Bio-rad Laboratories, Inc
    • 12.3.14.1. Company Overview
    • 12.3.14.2. Financial Performance
    • 12.3.14.3. Product Benchmarking
    • 12.3.14.4. Strategic Initiatives
  • 12.3.15. Perkinelmer Inc
    • 12.3.15.1. Company Overview
    • 12.3.15.2. Financial Performance
    • 12.3.15.3. Product Benchmarking
    • 12.3.15.4. Strategic Initiatives
  • 12.3.16. Myriad Genetics, Inc.
    • 12.3.16.1. Company Overview
    • 12.3.16.2. Financial Performance
    • 12.3.16.3. Product Benchmarking
    • 12.3.16.4. Strategic Initiatives
  • 12.3.17. Sysmex Corporation
    • 12.3.17.1. Company Overview
    • 12.3.17.2. Financial Performance
    • 12.3.17.3. Product Benchmarking
    • 12.3.17.4. Strategic Initiatives
  • 12.3.18. Neogenomics Laboratories, Inc
    • 12.3.18.1. Company Overview
    • 12.3.18.2. Financial Performance
    • 12.3.18.3. Product Benchmarking
    • 12.3.18.4. Strategic Initiatives
  • 12.3.19. Exact Sciences Corporation
    • 12.3.19.1. Company Overview
    • 12.3.19.2. Financial Performance
    • 12.3.19.3. Product Benchmarking
    • 12.3.19.4. Strategic Initiatives
  • 12.3.20. Grail
    • 12.3.20.1. Company Overview
    • 12.3.20.2. Financial Performance
    • 12.3.20.3. Product Benchmarking
    • 12.3.20.4. Strategic Initiatives
  • 12.3.21. Guardant Health Inc,.
    • 12.3.21.1. Company Overview
    • 12.3.21.2. Financial Performance
    • 12.3.21.3. Product Benchmarking
    • 12.3.21.4. Strategic Initiatives
  • 12.3.22. Tempus
    • 12.3.22.1. Company Overview
    • 12.3.22.2. Financial Performance
    • 12.3.22.3. Product Benchmarking
    • 12.3.22.4. Strategic Initiatives
  • 12.3.23. Delfi Diagnostics
    • 12.3.23.1. Company Overview
    • 12.3.23.2. Financial Performance
    • 12.3.23.3. Product Benchmarking
    • 12.3.23.4. Strategic Initiatives
  • 12.3.24. Adela, Inc
    • 12.3.24.1. Company Overview
    • 12.3.24.2. Financial Performance
    • 12.3.24.3. Product Benchmarking
    • 12.3.24.4. Strategic Initiatives
  • 12.3.25. Clearnote Health
    • 12.3.25.1. Company Overview
    • 12.3.25.2. Financial Performance
    • 12.3.25.3. Product Benchmarking
    • 12.3.25.4. Strategic Initiatives
  • 12.3.26. Natera
    • 12.3.26.1. Company Overview
    • 12.3.26.2. Financial Performance
    • 12.3.26.3. Product Benchmarking
    • 12.3.26.4. Strategic Initiatives
• 12.4. Strategy Mapping
  • 12.4.1. Expansion
  • 12.4.2. Acquisition
  • 12.4.3. Collaborations
  • 12.4.4. Disease Type/drug Class Launch
  • 12.4.5. Partnerships
  • 12.4.6. Others
• 12.5. Distribution Model Analysis For Major Players
• 12.6. Competitive Heat Map Analysis For U.S. Cancer Diagnostics Market, 2024
• 12.7. Competitive Heat Map Analysis For Uk Cancer Diagnostics Market, 2024
• 12.8. List Of Cancers Of Unknown Primary Diagnostics Companies
• 12.9. Guardant Test Evaluation

Chapter 13. Conclusion/key Takeways